Skip to main content

Osteoporosis Screening in the Reconstructive Urology & Urogynecology Patient

Reconstructive practices care for patients at risk of bone loss from menopause, GnRH therapy, aromatase inhibitors, androgen deprivation and systemic glucocorticoids used for other conditions.[1] The AUA advises against long-term systemic oral glucocorticoids as primary IC/BPS therapy (Recommendation; Grade C).[12] Vertebral fractures can impair mobility and complicate operative positioning; hip fractures in this population carry substantial morbidity and mortality. The 2025 USPSTF reaffirmed a Grade B recommendation for dual-energy x-ray absorptiometry (DXA) screening in women aged ≥ 65 years without known osteoporosis, prior fragility fracture, or secondary osteoporosis, and in younger postmenopausal women at increased fracture risk as estimated by clinical risk assessment.[2]

Who to Screen​

Universal threshold: ≥ 65 years​

DXA screening is recommended for postmenopausal women aged ≥65 years without known osteoporosis, prior fragility fracture, or secondary osteoporosis, without additional risk-factor assessment.[2] For men aged ≥40 years without known osteoporosis, prior fragility fracture, or secondary osteoporosis, the USPSTF finds evidence insufficient for population screening; ISCD indicates DXA at age ≥70 years or earlier with low-bone-mass risk factors, and androgen-deprivation therapy warrants targeted bone-risk assessment.[2][7][13]

Younger postmenopausal women (< 65 years)​

A practical two-step approach applies to younger postmenopausal women:

  1. Identify clinical risk factors such as low weight, parental hip fracture, smoking or excess alcohol.
  2. If risk factors are present, use a validated osteoporosis or fracture-risk tool to decide on DXA. USPSTF 2025 does not define 9.3% FRAX as a screening threshold; that figure illustrates a reference patient’s risk.[2]

Risk factors warranting earlier screening​

CategoryExamples
GU / gynecologic treatmentsGnRH agonists (preoperative priming, endometriosis, fibroids), aromatase inhibitors (breast cancer survivors), prolonged estrogen deprivation
Other medicationsSystemic glucocorticoids ≥2.5 mg/day prednisone-equivalent for >3 months warrant dedicated risk assessment[9], anticonvulsants, depot medroxyprogesterone acetate[3]
AnthropometricLow body weight (<127 lb / 57.6 kg), BMI <20 kg/m²
LifestyleCurrent smoking, alcohol >3 drinks/day
Medical conditionsRheumatoid arthritis, type 1 or 2 diabetes, hyperparathyroidism, celiac disease / malabsorption syndromes
Family historyParental history of hip fracture
ReproductivePremature ovarian insufficiency (<40 years), early menopause (40–44 years), premenopausal bilateral salpingo-oophorectomy, prolonged amenorrhea

At diagnosis of premature ovarian insufficiency, the 2024 international guideline strongly recommends baseline DXA where available.[17] After premenopausal risk-reducing salpingo-oophorectomy, the 2023 international consensus strongly recommends DXA within the first year.[18]

GnRH therapy. Bone loss, treatment-duration limits and add-back depend on the product and indication. Leuprolide 11.25 mg IM every three months may be given with or without norethindrone acetate 5 mg daily for an initial course of up to six months; retreatment requires add-back and prior BMD assessment, with total therapy limited to 12 months. The fibroid indication is a three-month course with iron for preoperative anemia and is not labeled for use with add-back. Do not automatically prescribe estrogen-progestin or a bisphosphonate for every short course.[10]

Diagnosis​

In postmenopausal women and men aged 50 or older, osteoporosis assessment includes:[1][6]

  • DXA T score ≤ −2.5 at the lumbar spine, total hip, femoral neck, or 33% radius when hip or spine cannot be measured or interpreted, in hyperparathyroidism, or above the DXA table weight limit.[7]
  • Hip or vertebral fragility fracture supports treatment regardless of BMD. Fractures at other sites require assessment of BMD, mechanism and clinical risk rather than an automatic diagnosis from any fracture.[8]

Osteopenia is defined as a T score between −1.0 and −2.5; fracture history and, when appropriate, FRAX estimates guide treatment decisions in this range.[8]

T scores are compared to a young-adult reference population (female, age 20–29); Z scores compare with age-matched peers and are preferred in premenopausal women and men younger than 50. T scores are used in men aged 50 or older; BMD alone does not diagnose osteoporosis in a younger man.[7]

When the T score is <−1.0, ISCD indicates DXA vertebral fracture assessment or lateral spine radiography for women aged ≥70 or men aged ≥80, or for patients with historical height loss >4 cm, a self-reported but undocumented prior vertebral fracture, or glucocorticoid therapy at a prednisone-equivalent dose ≥5 mg/day for ≥3 months.[7]

FRAX and Risk Stratification​

FRAX combines age, sex, BMI, and selected clinical risk factors to estimate 10-year hip and major osteoporotic fracture probabilities; its omission of falls and type 2 diabetes may underestimate risk for affected patients.[2] It can be run with or without femoral-neck BMD; adding femoral-neck BMD improves predictive accuracy. In cancer survivors starting androgen-deprivation therapy, aromatase inhibitors or GnRH agonists, FRAX may underestimate treatment-related fracture risk; ASCO advises recording secondary osteoporosis when using FRAX in these groups.[13]

For postmenopausal women and men aged ≥50 years, BHOF advises considering pharmacologic treatment when any of the following criteria is met:[1][6][8]

CriterionThreshold
Fragility fractureHip or vertebral fracture: consider treatment regardless of BMD; proximal humerus, pelvis, or distal forearm fracture with osteopenia: consider treatment.[8]
DXA T score≤ −2.5 at femoral neck, total hip, lumbar spine, or 33% radius when indicated (with some uncertainty for the radius threshold).[7][8]
Osteopenia + FRAXFemoral-neck or total-hip T score between −1.0 and −2.5 and either 10-year hip fracture probability ≥3% or major osteoporotic fracture probability ≥20% (US-adapted FRAX)[8]

Risk is then stratified into high versus very high risk to guide agent selection (see Treatment below).

Screening and monitoring intervals​

USPSTF 2025 supports screening women aged 65 or older and younger postmenopausal women at increased risk, but does not specify a single rescreening interval.[2]

Separate repeat screening from treatment monitoring. Age, baseline BMD, new fractures, medication exposure and expected rate of change determine timing. Observational 10–15-year estimates concern older women with near-normal BMD; individual rescreening timing depends on clinical risk.[2] BHOF suggests reassessment one to two years after starting or changing osteoporosis therapy, then individualized intervals.[3][4][5][8]

For ongoing systemic glucocorticoids, the American College of Rheumatology recommends risk assessment for adults taking ≥2.5 mg/day for more than three months, including BMD and vertebral assessment; reassessment is commonly every one to two years according to risk. This is distinct from the American College of Radiology imaging criteria.[9]

Treatment Overview​

High fracture risk​

Agent choice depends on fractures, BMD, renal function, contraindications and adherence. Antiresorptives are commonly used:[1][6]

  • Oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly) are recommended initial options for postmenopausal women at high fracture risk when appropriate, with low cost and extensive safety data.[8]
  • IV zoledronic acid 5 mg annually is an option when oral adherence or GI tolerance is a concern. Before infusion, correct hypocalcemia, ensure hydration, and check creatinine clearance; infuse over at least 15 minutes. Reclast is contraindicated with hypocalcemia, creatinine clearance <35 mL/min, or acute renal impairment.[15]
  • Denosumab 60 mg SC every six months.[8] In advanced CKD, especially dialysis or CKD-MBD, FDA warns of severe hypocalcemia; CKD-MBD specialist assessment includes calcium and bone-disease evaluation, correction of hypocalcemia, calcium and activated vitamin D supplementation, and close calcium monitoring for 2–10 weeks after each injection.[11] Discontinuation or delayed dosing requires a subsequent antiresorptive plan because of rebound vertebral fracture risk.[8][11]
  • Raloxifene (SERM) has a modest vertebral-fracture benefit and no demonstrated hip-fracture benefit; it may be considered in selected postmenopausal women at increased breast-cancer risk.[8] It is contraindicated with current or prior venous thromboembolism; the label directs interruption at least 72 hours before and throughout prolonged immobilization, with resumption only once fully ambulatory.[16] In the randomized RUTH trial of 10,101 postmenopausal women with coronary disease or elevated coronary risk (median follow-up 5.6 years), fatal stroke occurred in 59/5,044 (1.2%) taking raloxifene versus 39/5,057 (0.8%) taking placebo; the label advises weighing this risk in women at risk for stroke.[16]

Very high fracture risk​

Recent or multiple fractures, very low BMD and other major risk factors may favor an anabolic-first strategy.[1]

  • Teriparatide duration and osteosarcoma-risk precautions require specialist review; use beyond two years is considered only when fracture risk remains or becomes high, and use should be avoided after skeletal radiation or with bone metastases or a history of skeletal malignancy.[8]
  • Romosozumab (anti-sclerostin) 210 mg SC monthly for 12 months has dual anabolic and antiresorptive effects. Do not initiate it in patients who had myocardial infarction or stroke within the preceding year.[8]
  • Follow with antiresorptive therapy after anabolic course to consolidate gains.

Calcium and vitamin D​

For adults aged 50 years or older receiving osteoporosis therapy, age- and sex-specific total calcium intake (1,000–1,200 mg/day) and vitamin D 800–1,000 IU/day as needed to achieve sufficiency are adjuncts, with dietary calcium preferred.[8] Some studies have linked calcium supplements with cardiovascular risk, but the evidence is conflicting.[8]

GU-Specific Considerations​

  • Hormone exposure. Low-dose vaginal estrogen is not a treatment for osteoporosis. For GnRH therapy, follow the indication-specific label and assess individual bone risk rather than requiring the same add-back and DXA schedule for every short course.[10]
  • Mobility and positioning. Review vertebral pain, falls, balance and ability to tolerate operative positioning.
  • Cancer survivors on AIs or ADT. Assess fracture risk and BMD, then choose bone-directed treatment according to risk and oncology context. ASCO generally supports DXA about every two years, with shorter intervals when clinically indicated; annual DXA and automatic antiresorptive co-treatment are not required for every patient.[13] For women with hormone-sensitive breast cancer receiving aromatase inhibitors, the 2025 joint position statement recommends antiresorptive therapy when the lowest spine or hip T score is <−2.0, at least two specified risk factors are present, or annual BMD falls ≥10% at any site (≥4–5% with baseline osteopenia) on the same DXA machine; rapid loss prompts evaluation for secondary causes.[14] Women with T score >−2.0 and no additional risk factors undergo fracture-risk and BMD review at 1–2-year intervals.[14]
  • Chronic systemic glucocorticoids. Use the dedicated rheumatology risk framework and reassess exposure, BMD, vertebral fractures and age. Do not apply a universal T-score −1.5 treatment trigger or assume chronic oral steroids are indicated for Hunner lesions.[9][12]

References​

1. Walker MD, Shane E. "Postmenopausal Osteoporosis." N Engl J Med. 2023;389(21):1979–1991. doi:10.1056/NEJMcp2307353

2. US Preventive Services Task Force, Nicholson WK, Silverstein M, et al. "Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement." JAMA. 2025;333(6):498–508. doi:10.1001/jama.2024.27154

3. White L. "Osteoporosis Prevention, Screening, and Diagnosis: ACOG Recommendations." Am Fam Physician. 2022;106(5):587–588. PMID 36379483

4. Expert Panel on Musculoskeletal Imaging, Yu JS, Krishna NG, et al. "ACR Appropriateness Criteria® Osteoporosis and Bone Mineral Density: 2022 Update." J Am Coll Radiol. 2022;19(11S):S417–S432. doi:10.1016/j.jacr.2022.09.007

5. Plesa M, Wong A, Katsaggelos E. "Health Maintenance in Postmenopausal Women." Am Fam Physician. 2025;111(5):407–418. PMID 40378321

6. Morin SN, Leslie WD, Schousboe JT. "Osteoporosis: A Review." JAMA. 2025;334(10):894–907. doi:10.1001/jama.2025.6003

7. ISCD. Official Adult Positions, 2023. BMD interpretation and follow-up.

8. LeBoff MS, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022. BHOF guidance.

9. Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res. 2023;75(12):2405-2419. doi:10.1002/acr.25240.

10. FDA. LUPRON DEPOT 11.25 mg prescribing information, 2025. Indication-specific duration and add-back.

11. FDA. Prolia: boxed warning for severe hypocalcemia in advanced CKD, 2024. Drug safety communication.

12. AUA. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome, 2022. Guideline.

13. Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(31):2916-2946. doi:10.1200/JCO.19.01696.

14. Hadji P, Aapro M, Al-Dagri N, et al. "Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG." J Bone Oncol. 2025;53:100694. doi:10.1016/j.jbo.2025.100694

15. US Food and Drug Administration. Reclast (zoledronic acid) injection: prescribing information. 2026. FDA label

16. Eli Lilly and Company. Evista (raloxifene hydrochloride): prescribing information. DailyMed, 2025. Drug label

17. Panay N, Anderson RA, Bennie A, et al. "Evidence-based guideline: premature ovarian insufficiency." Hum Reprod Open. 2024;2024(4):hoae065. doi:10.1093/hropen/hoae065

18. Nebgen DR, Domchek SM, Kotsopoulos J, et al. "Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations." BJOG. 2023;130(12):1437–1450. doi:10.1111/1471-0528.17511